|Bid||3.9800 x 21500|
|Ask||4.0100 x 900|
|Day's Range||3.9800 - 4.0000|
|52 Week Range||2.4300 - 14.5300|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2020 - Mar 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.39|
BALA CYNWYD, PA / ACCESSWIRE / December 18, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" ...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
NEW YORK, NY / ACCESSWIRE / December 14, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) in connection with the proposed acquisition of the Company by UnitedHealth Group's (NYSE: UNH) OptumRx. Under the terms of the acquisition agreement, DPLO shareholders will receive $4 per share in cash.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Diplomat Pharmacy, Inc. (NYSE: DPLO) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to UnitedHealth Group Inc.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) relating to the sale of the Company to UnitedHealth Group Incorporated. Under the terms of the Merger, Diplomat shareholders will have the right to receive $4.00 in cash for each Diplomat common stock owned.
Moody's Investors Service ("Moody's") placed the ratings of Diplomat Pharmacy, Inc. ("Diplomat") under review for upgrade. Moody's changed the outlook to rating under review from developing. OptumRx is part of UnitedHealth Group Incorporated, which has senior unsecured debt rated A3 with a stable outlook.
Dow book a triple-digit loss Monday, and all three major U.S. stock indexes end lower, as investors wait on global central bank policy updates this week and a key tariff deadline on Sunday.
Benzinga Pro's Stocks To Watch For Monday Merck (MRK) - Reported it will purchase ArQule (ARQL) in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares were ...
You might think the hard-money, recession-at-every-corner crowd would be predicting an imminent reversal in the stock market given the 20% gain for the Dow Jones Industrial Average this year. Not necessarily.
Diplomat Pharmacy (NYSE: DPLO ) shares are trading lower on Monday after the company received a $4 per share acquisition offer from UnitedHealth Group's (NYSE: UNH ) OptumRx. Optum is UnitedHealth Group's ...
UnitedHealth Group Inc. said Monday it will spend about $300 million to acquire Diplomat Pharmacy Inc., a specialty pharmacist that had been struggling to compete in an industry increasingly dominated by health-industry giants.
UnitedHealth Group's OptumRx pharmacy care services unit is acquiring specialty pharmacy Diplomat Pharmacy Inc. for $4 a share in cash, the companies said Monday. Diplomat shares closed Friday at $5.81 and the stock tumbled 32% in premarket trade Monday. The stock has fallen 57% in 2019, after it disclosed a "going concern" warning in November as it reported a much wider-than-expected loss for a third straight quarter. Diplomat offers care in specialty medications that treat patients with complex diseases, such as oncology and immunology, and provides specialized infusion therapies in all 50 states and Washington, D.C., according to a release.
Diplomat Pharmacy Inc on Monday agreed to UnitedHealth Group Inc's over $300 million buyout offer, weeks after it warned of its inability to pay off some of its debt amid intense competition in the pharmacy benefits management business. Health insurer UnitedHealth's offer of $4 per share in cash is at a 31% discount to Diplomat's closing price on Friday and is a far cry from the company's peak market valuation in 2015, when its shares had traded as high as $52. "It's hard for me to call it (UnitedHealth's offer) a godsend on a stock that has gone from over $50 to now a take-under... I would not call this a great day for Diplomat," Baird analyst Eric Coldwell told Reuters.
Diplomat, the Flint, Mich., pharmacy- and infusion-services provider, had considered a number of strategic options.
Diplomat Pharmacy, Inc. (NYSE:DPLO) investors will be delighted, with the company turning in some strong numbers with...
Diplomat Pharmacy Inc (NYSE: DPLO) cautioned investors on Tuesday that it has "substantial doubts" related to its ability to continue functioning as a business. Wells Fargo analyst Jamie Stockton maintained a Market Perform rating on Diplomat with a price target lowered from $5.50 to $3. If the company opts not to sell itself and remain public, it would be valued at eight times EV/EBITDA on EBITDA estimates of $85 million, the analyst said.
Shares of Diplomat Pharmacy Inc. took a record dive Tuesday after the specialty pharmacy company disclosed a “going concern” warning as the company reported a much wider-than-expected loss for a third straight quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD, the senior secured rating to Caa1 from B3 and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3. The downgrade of the Corporate Family Rating to Caa1 from B3 reflects the recent decision by a large payer to begin excluding Diplomat from its specialty pharmacy network later this month, raising concerns about Diplomat's competitive position.
Shares of Diplomat Pharmacy, Inc. (NYSE: DPLO), a Flint, Michigan-based independent provider of specialty pharmacy and infusion services, plummeted more than 50% Tuesday after the company warned investors it faces an existential threat. Revenue declined year-over-year from $1.373 billion to $1.301 million, and the pharmacy benefit manager segment revenue fell from $170 million to $82 million as the segment's total volume fell from 1,931,000 to 922,000. Diplomat's earnings report includes a warning that it may not be able to meet its total net leverage and interest coverage ratio covenants as part of its credit agreement for the period ending Dec. 31, 2019.
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?